Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Cash from Financing Activities (2016 - 2025)

Mimedx (MDXG) has disclosed Cash from Financing Activities for 15 consecutive years, with -$583000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 45.75% to -$583000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.4 million through Dec 2025, up 84.17% year-over-year, with the annual reading at -$5.4 million for FY2025, 84.17% up from the prior year.
  • Cash from Financing Activities hit -$583000.0 in Q4 2025 for Mimedx, up from -$857000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $370000.0 in Q3 2023 to a low of -$33.5 million in Q1 2024.
  • Historically, Cash from Financing Activities has averaged -$2.6 million across 5 years, with a median of -$379500.0 in 2024.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 200.0% in 2022 and later tumbled 836575.0% in 2024.
  • Year by year, Cash from Financing Activities stood at $22000.0 in 2021, then surged by 200.0% to $66000.0 in 2022, then plummeted by 13645.45% to -$8.9 million in 2023, then skyrocketed by 95.53% to -$400000.0 in 2024, then crashed by 45.75% to -$583000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for MDXG at -$583000.0 in Q4 2025, -$857000.0 in Q3 2025, and -$1.1 million in Q2 2025.